What is Achiko?
Headquartered in Zurich with a robust presence across Asia, Achiko operates at the intersection of biotechnology and digital mobile health. The company is structured around two primary pillars: AptameX, which focuses on DNA aptamer-based diagnostic technology, and Teman Sehat, a digital mobile health platform. This unique synergy allows Achiko to provide comprehensive, user-friendly diagnostic testing that is seamlessly integrated with digital passport solutions. By leveraging technology licensed from Regenacellx.sl, the company aims to deliver cost-effective and rapid testing capabilities for a wide range of pathogenic diseases, positioning itself as a disruptive force in the global diagnostic market.
How much funding has Achiko raised?
Achiko has raised a total of $19.3M across 3 funding rounds:
Share Placement
$5.3M
Debt
$12.7M
Debt
$1.3M
Share Placement (2021): $5.3M, investors not publicly disclosed
Debt (2022): $12.7M led by Riverfort Global Opportunities PCC
Debt (2022): $1.3M supported by Buranto and Negma Group
Key Investors in Achiko
Buranto
Buranto is a smart investment firm run by Annette and Derek Brandt that specializes in identifying high-growth opportunities and providing strategic financial planning for both individual and corporate clients.
Negma Group
Negma Group is a diversified investment fund focused on debt and equity financing, venture capital, and quantitative trading strategies, with a track record of supporting innovative growth-stage companies.
Riverfort Global Opportunities PCC
Riverfort Global Opportunities PCC is an investment vehicle that provides flexible capital solutions to support the strategic development and operational scaling of emerging technology firms.
What's next for Achiko?
With the recent capital infusion, Achiko is well-positioned to accelerate the commercial deployment of its AptameX diagnostic platform. The strategic focus will likely center on expanding the reach of the Teman Sehat application, enhancing its utility as a digital health ecosystem. Furthermore, the company is expected to prioritize the scaling of its manufacturing and distribution networks to meet the growing demand for affordable, rapid diagnostic tools. By maintaining its commitment to innovation and strategic partnerships, Achiko aims to solidify its market share and drive long-term value in the competitive healthtech arena.
See full Achiko company page
